Vienna, Austria — BioneXt LAB today announced the launch of CoVive, a free support and monitoring app developed in rapid response to the ongoing global outbreak and spread of COVID-19. Developed as a global initiative in partnership with Medicus AI, the app is available on iOS and is coming soon to Android.
Available globally, CoVive works to relieve pressure on healthcare systems to help ‘flatten the curve’. By empowering users with more clarity and information about their health, with features for self-assessment, test interpretation, and self-monitoring, the app acts as a reassuring companion and source of reliable information and proposed next steps for users.
“As a lab, we understand the unprecedented pressures on healthcare systems associated with an outbreak, from every angle, and in every city around the world working to manage these new and alarming pressures. Prioritizing clear and meaningful communication with patients has always driven our innovation at BioneXt, and we saw an opportunity to create a service that could be useful to patients and to healthcare providers everywhere. By providing patients with reliable information and actionable steps, the app works to support all stakeholders in the ecosystem,” said Dr. Jean-Luc Dourson, CEO and Founder, BioneXt LAB.
“In a pandemic, people feel scared and have a heightened tendency to panic. The early weeks of the COVID-19 outbreak brought with it an avalanche of misinformation and much uncertainty and very quickly we worked with BioneXt to discuss how we could support and build something useful and meaningful for users. CoVive comes from what we do naturally at Medicus, in providing personalized interpretation and intuitive communication, so this is where we focused the value we could create for CoVive users,” said Dr. Baher Al Hakim, CEO, Medicus AI.
From its HQ in Luxembourg, BioneXt worked closely with Medicus AI to customize and localize CoVive to multiple countries, and in multiple languages, always supported by official local guidelines and local sources to provide relevant and up-to-date information that is in line with each country’s guidelines, contact information, and recommendations.
CoVive is a regulated medical product and is the first SARS-CoV-2 app to receive a CE medical device class 1 certification.
“Completing the CE certification in such a short time was nothing short of miraculous, with our teams working day and night to get it done in record time. At Medicus, we take the issue of regulation and medical certification very seriously, even though the timing was critical, we couldn’t take any shortcuts here,” said Dr. Baher Al Hakim.
CoVive is available to download for free on iOS and is coming soon to Android. In its initial phase, CoVive is available in English, French, German, Portuguese, Greek, and Arabic.
The CoVive platform is powered by Medicus AI, a global digital healthcare company working with diagnostic labs, clinics, and insurers that offers a range of medical and CE certified products in its portfolio.
For more information, visit www.covive.ai.
Send us your press releases to pressrelease.zawya@refinitiv.com
© Press Release 2020Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.
The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.
To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.
